Anixa Price To Sales Ratio vs Capex To Revenue Analysis

ANIX Stock

USD 3.32 0.10 3.11%

Anixa Biosciences financial indicator trend analysis is way more than just evaluating Anixa Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Anixa Biosciences is a good investment. Please check the relationship between Anixa Biosciences Price To Sales Ratio and its Capex To Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anixa Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Anixa Stock please use our How to Invest in Anixa Biosciences guide.

Price To Sales Ratio vs Capex To Revenue

Price To Sales Ratio vs Capex To Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Anixa Biosciences Price To Sales Ratio account and Capex To Revenue. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Anixa Biosciences' Price To Sales Ratio and Capex To Revenue is 0.58. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of Anixa Biosciences, assuming nothing else is changed. The correlation between historical values of Anixa Biosciences' Price To Sales Ratio and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Anixa Biosciences are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Price To Sales Ratio i.e., Anixa Biosciences' Price To Sales Ratio and Capex To Revenue go up and down completely randomly.

Correlation Coefficient

0.58

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Anixa Biosciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Anixa Biosciences sales, a figure that is much harder to manipulate than other Anixa Biosciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most indicators from Anixa Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Anixa Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anixa Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Anixa Stock please use our How to Invest in Anixa Biosciences guide.At this time, Anixa Biosciences' Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value is likely to rise to about 134.2 M in 2024, whereas Selling General Administrative is likely to drop slightly above 4.2 M in 2024.

Anixa Biosciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Non Currrent Assets Other	Net Receivables	Accounts Payable	Non Current Liabilities Total	Common Stock Total Equity	Short Term Investments	Common Stock	Other Assets	Property Plant Equipment
Total Assets		0.81	0.39	0.98	0.43	-0.55	-0.67	0.53	-0.54	0.99	0.88	0.2	0.3	0.82	-0.29	0.43	0.99	-0.2	-0.34	-0.61	-0.52	-0.32	0.81	-0.32	-0.23	0.64
Other Current Liab	0.81		0.63	0.8	0.21	-0.13	-0.67	0.07	-0.53	0.8	0.89	0.02	0.5	0.84	-0.23	0.21	0.81	-0.17	-0.32	-0.38	-0.53	-0.12	0.91	-0.12	-0.26	0.5
Total Current Liabilities	0.39	0.63		0.28	-0.29	0.21	-0.45	-0.15	0.17	0.32	0.47	0.08	0.27	0.52	0.47	-0.29	0.34	-0.18	-0.47	0.03	0.14	0.47	0.54	0.47	-0.44	-0.05
Total Stockholder Equity	0.98	0.8	0.28		0.51	-0.59	-0.65	0.54	-0.67	1.0	0.9	0.13	0.36	0.81	-0.46	0.51	1.0	-0.19	-0.27	-0.63	-0.67	-0.44	0.8	-0.44	-0.15	0.7
Property Plant And Equipment Net	0.43	0.21	-0.29	0.51		-0.46	0.05	0.44	-0.71	0.49	0.3	0.0	0.38	0.08	-0.61	1.0	0.48	-0.13	0.4	-0.53	-0.61	-0.51	0.26	-0.51	0.56	0.92
Net Debt	-0.55	-0.13	0.21	-0.59	-0.46		0.29	-0.98	0.4	-0.59	-0.32	0.05	0.0	-0.25	0.41	-0.46	-0.56	0.12	0.19	0.37	0.41	0.27	0.01	0.27	0.03	-0.34
Retained Earnings	-0.67	-0.67	-0.45	-0.65	0.05	0.29		-0.28	0.36	-0.66	-0.82	0.21	-0.46	-0.92	0.12	0.05	-0.67	0.05	0.85	0.02	0.32	0.34	-0.59	0.34	0.78	-0.15
Cash	0.53	0.07	-0.15	0.54	0.44	-0.98	-0.28		-0.32	0.56	0.27	-0.02	-0.05	0.23	-0.29	0.44	0.53	-0.03	-0.22	-0.32	-0.3	-0.22	-0.05	-0.22	-0.06	0.31
Non Current Assets Total	-0.54	-0.53	0.17	-0.67	-0.71	0.4	0.36	-0.32		-0.62	-0.66	0.33	-0.54	-0.47	0.88	-0.71	-0.62	-0.02	-0.09	0.46	0.94	0.74	-0.5	0.74	-0.23	-0.77
Cash And Short Term Investments	0.99	0.8	0.32	1.0	0.49	-0.59	-0.66	0.56	-0.62		0.89	0.14	0.34	0.81	-0.38	0.49	1.0	-0.18	-0.31	-0.62	-0.6	-0.39	0.8	-0.39	-0.19	0.68
Common Stock Shares Outstanding	0.88	0.89	0.47	0.9	0.3	-0.32	-0.82	0.27	-0.66	0.89		-0.12	0.57	0.95	-0.38	0.3	0.9	-0.22	-0.49	-0.44	-0.63	-0.44	0.87	-0.44	-0.37	0.58
Inventory	0.2	0.02	0.08	0.13	0.0	0.05	0.21	-0.02	0.33	0.14	-0.12		-0.48	-0.09	0.28	0.0	0.15	0.11	0.3	-0.12	0.25	0.22	0.2	0.22	0.11	0.05
Other Current Assets	0.3	0.5	0.27	0.36	0.38	0.0	-0.46	-0.05	-0.54	0.34	0.57	-0.48		0.51	-0.35	0.38	0.35	-0.2	-0.27	0.03	-0.47	-0.37	0.44	-0.37	-0.16	0.52
Other Stockholder Equity	0.82	0.84	0.52	0.81	0.08	-0.25	-0.92	0.23	-0.47	0.81	0.95	-0.09	0.51		-0.2	0.08	0.82	-0.11	-0.68	-0.25	-0.44	-0.38	0.81	-0.38	-0.62	0.38
Total Liab	-0.29	-0.23	0.47	-0.46	-0.61	0.41	0.12	-0.29	0.88	-0.38	-0.38	0.28	-0.35	-0.2		-0.61	-0.38	0.02	-0.25	0.35	0.93	0.76	-0.22	0.76	-0.35	-0.59
Property Plant And Equipment Gross	0.43	0.21	-0.29	0.51	1.0	-0.46	0.05	0.44	-0.71	0.49	0.3	0.0	0.38	0.08	-0.61		0.48	-0.13	0.4	-0.53	-0.61	-0.51	0.26	-0.51	0.56	0.92
Total Current Assets	0.99	0.81	0.34	1.0	0.48	-0.56	-0.67	0.53	-0.62	1.0	0.9	0.15	0.35	0.82	-0.38	0.48		-0.18	-0.3	-0.62	-0.6	-0.39	0.82	-0.39	-0.19	0.68
Non Currrent Assets Other	-0.2	-0.17	-0.18	-0.19	-0.13	0.12	0.05	-0.03	-0.02	-0.18	-0.22	0.11	-0.2	-0.11	0.02	-0.13	-0.18		0.08	0.45	0.1	-0.11	-0.18	-0.11	-0.06	-0.18
Net Receivables	-0.34	-0.32	-0.47	-0.27	0.4	0.19	0.85	-0.22	-0.09	-0.31	-0.49	0.3	-0.27	-0.68	-0.25	0.4	-0.3	0.08		-0.28	-0.12	0.04	-0.2	0.04	0.95	0.26
Accounts Payable	-0.61	-0.38	0.03	-0.63	-0.53	0.37	0.02	-0.32	0.46	-0.62	-0.44	-0.12	0.03	-0.25	0.35	-0.53	-0.62	0.45	-0.28		0.45	0.26	-0.52	0.26	-0.42	-0.63
Non Current Liabilities Total	-0.52	-0.53	0.14	-0.67	-0.61	0.41	0.32	-0.3	0.94	-0.6	-0.63	0.25	-0.47	-0.44	0.93	-0.61	-0.6	0.1	-0.12	0.45		0.66	-0.49	0.66	-0.25	-0.68
Common Stock Total Equity	-0.32	-0.12	0.47	-0.44	-0.51	0.27	0.34	-0.22	0.74	-0.39	-0.44	0.22	-0.37	-0.38	0.76	-0.51	-0.39	-0.11	0.04	0.26	0.66		-0.29	1.0	-0.03	-0.55
Short Term Investments	0.81	0.91	0.54	0.8	0.26	0.01	-0.59	-0.05	-0.5	0.8	0.87	0.2	0.44	0.81	-0.22	0.26	0.82	-0.18	-0.2	-0.52	-0.49	-0.29		-0.29	-0.17	0.59
Common Stock	-0.32	-0.12	0.47	-0.44	-0.51	0.27	0.34	-0.22	0.74	-0.39	-0.44	0.22	-0.37	-0.38	0.76	-0.51	-0.39	-0.11	0.04	0.26	0.66	1.0	-0.29		-0.03	-0.55
Other Assets	-0.23	-0.26	-0.44	-0.15	0.56	0.03	0.78	-0.06	-0.23	-0.19	-0.37	0.11	-0.16	-0.62	-0.35	0.56	-0.19	-0.06	0.95	-0.42	-0.25	-0.03	-0.17	-0.03		0.4
Property Plant Equipment	0.64	0.5	-0.05	0.7	0.92	-0.34	-0.15	0.31	-0.77	0.68	0.58	0.05	0.52	0.38	-0.59	0.92	0.68	-0.18	0.26	-0.63	-0.68	-0.55	0.59	-0.55	0.4

Click cells to compare fundamentals

Anixa Biosciences Account Relationship Matchups

Anixa Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	9.5M	36.3M	30.4M	25.5M	29.4M	30.8M
Other Current Liab	845.8K	1.1M	1.7M	1.8M	2.0M	2.1M
Total Current Liabilities	1.2M	1.3M	2.0M	2.0M	2.3M	2.4M
Total Stockholder Equity	8.8M	35.4M	29.0M	24.3M	28.0M	29.4M
Property Plant And Equipment Net	54.3K	254.0K	212K	166K	149.4K	132.1K
Net Debt	(6.4M)	(28.9M)	(12.1M)	(740K)	(666K)	(699.3K)
Retained Earnings	(191.8M)	(204.8M)	(218.4M)	(228.2M)	(205.4M)	(195.1M)
Cash	6.4M	29.1M	12.4M	915K	1.1M	999.6K
Non Current Assets Total	84.3K	254.0K	212K	166K	190.9K	181.4K
Cash And Short Term Investments	9.1M	35.7M	29.7M	23.8M	27.4M	28.8M
Common Stock Shares Outstanding	22.2M	28.6M	30.4M	31.0M	35.6M	37.4M
Liabilities And Stockholders Equity	9.5M	36.3M	30.4M	25.5M	29.4M	30.8M
Inventory	1.0	(2.4M)	(2.6M)	(46K)	(41.4K)	(39.3K)
Other Current Assets	311.6K	551.6K	513K	1.2M	1.1M	1.2M
Other Stockholder Equity	200.4M	239.9M	247.1M	252.2M	290.1M	304.6M
Total Liab	1.2M	1.5M	2.2M	2.2M	2.5M	2.2M
Property Plant And Equipment Gross	54.3K	254.0K	212K	166K	149.4K	132.1K
Total Current Assets	9.4M	36.0M	30.2M	25.4M	29.2M	30.6M
Non Currrent Assets Other	910.2K	(200.6K)	30K	(212K)	(243.8K)	(231.6K)
Net Receivables	66.5K	2.2K	46K	270K	243K	231.6K
Accounts Payable	232.4K	136K	265K	206K	185.4K	176.1K
Non Current Liabilities Total	287.6K	220.1K	175K	123K	141.5K	134.4K
Common Stock Total Equity	189.1K	203.3K	242.5K	309K	278.1K	264.2K
Short Term Investments	2.6M	6.6M	17.3M	22.9M	26.4M	27.7M
Common Stock	242.5K	300.5K	309K	311K	279.9K	265.9K
Property Plant Equipment	200.6K	54.3K	254.0K	212K	243.8K	256.0K
Net Tangible Assets	5.2M	8.8M	35.4M	29.0M	33.4M	35.1M
Noncontrolling Interest In Consolidated Entity	(251.4K)	(423.0K)	(497.0K)	(847K)	(762.3K)	(724.2K)
Retained Earnings Total Equity	(170.2M)	(181.8M)	(191.8M)	(218.4M)	(196.5M)	(206.4M)
Capital Surpluse	175.4M	186.8M	200.4M	247.1M	284.2M	181.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Anixa Stock Analysis

When running Anixa Biosciences' price analysis, check to measure Anixa Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anixa Biosciences is operating at the current time. Most of Anixa Biosciences' value examination focuses on studying past and present price action to predict the probability of Anixa Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anixa Biosciences' price. Additionally, you may evaluate how the addition of Anixa Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Anixa Price To Sales Ratio vs Capex To Revenue Analysis

Price To Sales Ratio vs Capex To Revenue

Price To Sales Ratio vs Capex To Revenue Correlation Analysis

Correlation Coefficient

Price To Sales Ratio

Capex To Revenue

Anixa Biosciences fundamental ratios Correlations

Anixa Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Anixa Biosciences fundamental ratios Accounts

Also Currently Popular

Additional Tools for Anixa Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Cash And Short Term Investments	+ 0.99	Total Assets

Cash	- 0.98	Net Debt
Other Stockholder Equity	- 0.92	Retained Earnings
Common Stock Shares Outstanding	- 0.82	Retained Earnings
Property Plant Equipment	- 0.77	Non Current Assets Total
Property Plant And Equipment Gross	- 0.71	Non Current Assets Total
Non Current Assets Total	- 0.71	Property Plant And Equipment Net